{"entity":{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","aka":[],"tldr":"A phase 1/2 trial of TG4050 in head and neck squamous cell carcinoma, run by Transgene, active and no longer recruiting.","summary":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer is a phase 1/2 interventional study registered as NCT04183166 by Transgene, with 80 participants enrolled, started 2019-12-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: TG4050.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04183166","url":"https://clinicaltrials.gov/study/NCT04183166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["transgene"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04183166","phase":"1/2","setting":"A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.","sponsor":"Transgene","enrolled":80,"outcomes":[]},"route":"/trials/nct04183166/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/"}]}}